IV iron in high doses non-inferior to low doses in patients undergoing maintenance hemodialysis
In the Proactive IV Iron Therapy in Haemodialysis (PIVOTAL) trial, among patients undergoing hemodialysis, a high-dose intravenous (IV) iron regimen administered proactively was noninferior to a low-dose regimen administered reactively and resulted in lower doses of erythropoiesis-stimulating agent being administered; 29,757 IU vs 38,805 IU. The findings are published October 26, 2018 in the New England Journal of Medicine.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies